Scarica l'app Stockscreener
2.48
4.98%
-0.13
Dopo l'orario di chiusura:
2.54
0.06
+2.42%
Tuhura Biosciences Inc Borsa (HURA) Ultime notizie
TuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to “Sell” - Defense World
TuHURA Biosciences Amid Nasdaq Composite Volatility - Kalkine Media
Millennium Management LLC Invests $138,000 in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Approves Executive Salary Increases - TipRanks
TuHURA Biosciences announces executive salary increases - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - PR Newswire
TuHURA Says FDA Lifts Partial Hold on Skin Cancer Study - marketscreener.com
TuHURA Biosciences stock rises following FDA hold lift By Investing.com - Investing.com Nigeria
TuHURA Biosciences stock rises following FDA hold lift - Investing.com
FDA Removes Partial Clinical Hold On TuHURA Biosciences' Phase 3 Accelerated Approval Trial For IFx-2.0 In Advanced Or Metastatic Merkel Cell Carcinoma - marketscreener.com
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma - PR Newswire
Squarepoint Ops LLC Invests $223,000 in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Secures $12.6M for Strategic Initiatives - TipRanks
TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating - TipRanks
TuHURA Biosciences raises $15.5 million for cancer trials By Investing.com - Investing.com South Africa
TuHURA Biosciences, Inc. announced that it expects to receive $12.19 million in funding - MarketScreener
TuHURA Biosciences raises $15.5 million for cancer trials - Investing.com
Tuhura Biosciences Secures $12.5 Mln In Private Offering - MarketScreener
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy - The Malaysian Reserve
Northern Trust Corp Makes New Investment in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting - Quantisnow
TuHURA Biosciences: Encountering Serious Cash Issues And A Long Timeline - Seeking Alpha
Kineta and TuHURA Biosciences Announce Merger Agreement - TipRanks
Q3 EPS Estimate for TuHURA Biosciences Decreased by Analyst - Defense World
FY2027 Earnings Estimate for HURA Issued By Zacks Small Cap - Defense World
HURA: First Quarter 2025 Results - MSN
What is HC Wainwright’s Estimate for HURA FY2025 Earnings? - Defense World
HC Wainwright Reaffirms “Buy” Rating for TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Eagle-Tribune
TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update - marketscreener.com
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference - Citizen Tribune
TuHURA Biosciences (HURA) to Release Earnings on Tuesday - Defense World
Kineta Amends Merger Agreement with TuHURA Biosciences - TipRanks
TuHURA Biosciences Amends Merger Agreement with Kineta - TipRanks
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma - TipRanks
TuHURA Biosciences begins trial for metastatic cancer therapy By Investing.com - Investing.com Canada
TuHURA Biosciences begins trial for metastatic cancer therapy - Investing.com
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) - PR Newswire
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - ACCESS Newswire
Geode Capital Management LLC Buys New Holdings in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial - marketscreener.com
TuHURA Biosciences and Kineta present updated results of cancer candidates - TipRanks
TuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123 - Nasdaq
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Resea - Eastern Progress
Press Release Distribution & PR Platform - ACCESS Newswire
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - ACCESS Newswire
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):